Psoriasis Drugs Market Size & Growth Forecast 2026–2035, By Segments (Treatment, Route of Administration, Class, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Psoriasis Drugs Market size was valued at USD 22.86 Billion in 2025 and is projected to grow at a 10.7% CAGR from 2026 to 2035, reaching USD 63.18 Billion by 2035. The industry revenue for 2026 is estimated at USD 25.04 billion.
Get more details on this report
Request Free Sample ReportPsoriasis Drugs Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 40.97% share, supported by broad access to biologics, strong dermatology networks, established diagnosis pathways, and high treatment uptake with ongoing disease management.
- Asia Pacific is growing at 11.98% CAGR, driven by improved dermatology access, rising diagnosis rates, and expanding use of prescription therapies across larger patient populations.
Segment Momentum
- Biologics accounted for 49.16% of the market in 2025, supported by their established use in managing moderate to severe psoriasis and strong physician adoption for long-term disease control.
- Topical administration is expanding rapidly because it offers accessible, localized treatment for routine disease management, making it attractive for earlier-stage and less extensive psoriasis cases.
Market Expansion Drivers
- Expanding adoption of biologics and targeted immunotherapies improving moderate-to-severe psoriasis treatment outcomes.
- Rising psoriasis prevalence and associated comorbidities increasing demand for advanced chronic disease therapies.
- Growing biosimilar approvals enhancing affordability and widening patient access to biologic psoriasis treatments.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Key players in the psoriasis drugs market include AbbVie Inc. (United States), Johnson & Johnson (United States), Novartis AG (Switzerland), Eli Lilly and Company (United States), Amgen Inc. (United States), UCB S.A. (Belgium), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As biologics and targeted immunotherapies deliver stronger skin clearance and more durable disease control than many older systemic options, prescribing patterns in the psoriasis drugs market are shifting toward advanced therapies for moderate-to-severe patients. Dermatologists are increasingly prioritizing agents that act on specific inflammatory pathways because they can better align treatment choice with disease severity, prior therapy failure, and long-term management needs. This is influencing market adoption by extending treatment duration, supporting earlier escalation from conventional therapies, and reinforcing demand for premium branded and specialty products that are closely tied to specialist care and monitoring pathways.
Rising psoriasis prevalence and associated comorbidities increasing demand for advanced chronic disease therapies
A growing patient pool, combined with the frequent overlap of psoriasis with psoriatic arthritis, cardiovascular risk, metabolic disorders, and mental health burden, is making treatment decisions more complex and raising the need for therapies suited to long-term disease management. In the psoriasis drugs market, this pushes clinicians and health systems toward agents that can offer broader disease control, reduce flares, and fit chronic care pathways rather than serving as short-term symptom relief. The result is stronger demand for advanced therapies that justify sustained use through their role in managing both dermatologic severity and the wider clinical burden surrounding psoriasis.
Growing biosimilar approvals enhancing affordability and widening patient access to biologic psoriasis treatments
Biosimilar entry is changing purchasing and reimbursement dynamics in the psoriasis drugs market by lowering the cost barrier associated with biologic therapy. As more biosimilars receive approval, payers gain leverage to expand formulary inclusion, reduce restrictions tied to prior authorization or step therapy, and support earlier biologic use for eligible patients. That shift increases market penetration by bringing biologic treatment into reach for a broader segment of patients while also intensifying competition among manufacturers, which encourages wider contracting, distribution, and physician uptake of biologic psoriasis treatments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding adoption of biologics and targeted immunotherapies improving moderate-to-severe psoriasis treatment outcomes | 2.00% | High | North America, Europe | High | Near Term |
| Rising psoriasis prevalence and associated comorbidities increasing demand for advanced chronic disease therapies | 1.80% | Moderate | North America, Asia Pacific | High | Mid Term |
| Growing biosimilar approvals enhancing affordability and widening patient access to biologic psoriasis treatments | 1.50% | High | Europe, North America | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional share of the psoriasis drugs market in 2025, accounting for 40.97% share. This position is sustained by broad access to advanced biologics and systemic therapies, established diagnosis and treatment pathways, and strong prescribing activity through specialist dermatology networks. Market activity in the region is further reinforced by higher treatment uptake among diagnosed patients, where earlier intervention, therapy switching, and long-term disease management support steady demand across branded drug categories.
Asia Pacific is projected to expand at an 11.98% CAGR over the forecast period in the psoriasis drugs market, driven by improving access to dermatology care and rising treatment adoption across major population centers. Growth is accelerating as more patients move from underdiagnosis or limited topical management toward prescription-based therapies, while expanding healthcare infrastructure and wider availability of newer treatments improve practical access. The region’s momentum is also supported by a growing treated patient base, which is increasing the volume of physician consultations, diagnosis, and therapy initiation.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Evidence-Based Treatment PathwaysGermany emphasizes psoriasis drugs supported by robust clinical evidence and structured treatment guidelines. Healthcare providers evaluate therapies based on effectiveness, safety, and long-term disease management while integrating newer biologic options into routine care.
France 🇫🇷
Integrated Dermatology CareFrance prioritizes psoriasis drugs within coordinated dermatology care models that emphasize treatment continuity and patient quality of life. Growing interest in targeted therapies supports broader therapeutic choices for complex and chronic disease management.
Italy 🇮🇹
Personalized Therapy SelectionItaly encourages personalized psoriasis treatment strategies based on disease severity and patient response. Healthcare professionals increasingly evaluate innovative biologics alongside established therapies to optimize long-term clinical management and treatment adherence.
Japan 🇯🇵
Patient-Centered Disease ManagementJapan focuses on psoriasis drugs that balance sustained efficacy with patient safety and treatment adherence. Clinical practice increasingly incorporates targeted therapies while maintaining careful evaluation of long-term outcomes across diverse patient populations.
South Korea 🇰🇷
Biologic Therapy ExpansionSouth Korea is expanding the use of advanced psoriasis drugs through broader access to biologic and targeted treatments. Healthcare providers increasingly adopt innovative therapeutic options that improve disease control and support individualized patient management strategies.
United States 🇺🇸
Advanced Biologic AdoptionThe U.S. market prioritizes innovative biologics and targeted therapies for moderate-to-severe psoriasis management. Healthcare providers increasingly focus on personalized treatment selection, long-term disease control, and expanding access to therapies with favorable clinical outcomes.
Segment Leadership and Growth Trends
Psoriasis Drugs Market Share (%), Treatment, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportBiologics held a 49.16% share of the psoriasis drugs market in 2025, making them the leading treatment segment. This leadership is maintained through their established role in managing moderate to severe psoriasis, where targeted action and continued physician reliance support consistent demand. Within the psoriasis drugs market, biologics also benefit from strong adoption in patients requiring long-term disease control when conventional options may offer less durable outcomes.
Systemic treatment is the fastest-growing segment in the psoriasis drugs market as prescribing patterns expand around broader disease management needs and the practical demand for therapies that can address widespread or harder-to-control cases. Its momentum is supported by the need for treatment options that fit between topical management and advanced biologic use, giving systemic therapies a growth advantage as clinicians seek scalable approaches across varied patient severity levels.
Route of Administration Segment Analysis: Parenteral (Largest Segment) vs Topical (Fastest-Growing Segment)
In 2025, parenteral administration accounted for a 44.07% share of the psoriasis drugs market, reflecting its strongest position among route of administration segments. This dominance is closely tied to the strong presence of biologic therapies, which are commonly delivered through injectable formats and are widely used in patients with more severe disease burden. As a result, the psoriasis drugs market continues to see parenteral routes maintain leadership through their direct association with advanced treatment use.
Topical administration is emerging as the fastest-growing route in the psoriasis drugs market, influenced by practical demand for accessible and localized treatment options in routine disease management. Growth is being supported by continued use in earlier-stage and less extensive cases, where ease of application and suitability for ongoing symptom control make topical therapies more attractive relative to more intensive administration routes.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Treatment | Topicals, Systemic, Biologics | Biologics | Systemic |
| Route of Administration | Oral, Parenteral, Topical | Parenteral | Topical |
| Class | Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteriods, Others | Tumor Necrosis Factor Inhibitors | Interleukin Inhibitors |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Others | Hospital Pharmacies | Retail Pharmacies |
Competitive Landscape and Market Positioning
1. AbbVie Inc. (United States)
2. Johnson & Johnson (United States)
3. Novartis AG (Switzerland)
4. Eli Lilly and Company (United States)
5. Amgen Inc. (United States)
6. UCB S.A. (Belgium)
7. Boehringer Ingelheim International GmbH (Germany)
8. Bristol-Myers Squibb Company (United States)
9. Pfizer Inc. (United States)
The psoriasis drugs market is evolving through intensive clinical research focused on advanced biologic therapies. New treatment options are being introduced to address diverse patient needs and improve therapeutic outcomes. The psoriasis drugs market is also shaped by collaborative efforts that strengthen drug development pipelines.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Eli Lilly | Feb-26 | Eli Lilly advanced its immunology pipeline with continued development of IL-23 and JAK pathway-targeting therapies. The company is reinforcing its clinical-stage investment focus in autoimmune and inflammatory biologics, strengthening its long-term positioning in psoriasis and related dermatology indications through next-generation targeted treatment modalities. |
| Arcutis Biotherapeutics | May-25 | Arcutis Biotherapeutics received U.S. FDA approval for ZORYVE (roflumilast) topical foam 0.3% for plaque psoriasis in adults and adolescents. The approval expands its non-steroidal topical treatment portfolio and reinforces industry momentum toward differentiated, patient-friendly dermatology therapies beyond traditional biologic approaches. |
| Johnson & Johnson | Mar-25 | Johnson & Johnson reported Phase 3 ICONIC-LEAD clinical data for icotrokinra (JNJ-2113), an oral IL-23 receptor antagonist for moderate to severe plaque psoriasis. Results showed 65% of patients achieved clear or almost clear skin and 50% achieved PASI 90 at Week 16 versus placebo, supporting its potential competitive differentiation in oral biologic-class alternatives. |
| Teva and Alvotech | May-25 | Teva and Alvotech obtained FDA approval for interchangeability of SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab), improving biosimilar adoption dynamics in psoriasis treatment. The approval enhances patient access to lower-cost biologic alternatives and strengthens competitive pressure in the immunology biosimilars segment. |
| Johnson & Johnson | Apr-25 | Johnson & Johnson received European Commission approval for TREMFYA (guselkumab) for moderately to severely active ulcerative colitis, extending the IL-23 inhibitor beyond psoriasis into additional inflammatory indications. This expansion supports lifecycle extension strategy and strengthens its broader immunology franchise across multiple autoimmune disease categories. |
| Organon | Sep-24 | Organon entered into an agreement to acquire Dermavant Sciences, expanding its dermatology portfolio with VTAMA (tapinarof) cream for plaque psoriasis. The transaction strengthens Organon’s immuno-dermatology capabilities and integrates commercial infrastructure with established FDA-approved topical therapies, enhancing its competitive position in non-biologic psoriasis treatments. |
| Envista (Kerr Dental) | Oct-24 | Envista, through its Kerr brand, introduced ZenFlex CM, a heat-treated nickel-titanium rotary file designed for enhanced flexibility and durability in root canal shaping. The launch strengthens its endodontic portfolio by improving procedural efficiency and expanding adoption of advanced rotary file technologies in dental treatment workflows. |
| Septodont Holding and Micro-Mega | Jun-25 | Septodont Holding and Micro-Mega entered a commercial partnership to distribute endodontic product portfolios across Europe, the Middle East, Africa, and the UK. The collaboration expands geographic reach and strengthens commercial access for endodontic devices, supporting broader penetration of specialized dental treatment solutions in key international markets. |
| Dentsply Sirona | Oct-24 | Dentsply Sirona launched the X-Smart Pro+ and Reciproc Blue systems, offering a streamlined one-file endodontic solution with integrated apex locator functionality and reciprocating motion. The launch enhances procedural efficiency in root canal treatment and reinforces the company’s positioning in advanced endodontic instrumentation systems. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Psoriasis Drugs Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Psoriasis Drugs Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the psoriasis drugs market?
What are the growth projections for the psoriasis drugs industry?
How is the adoption of biologics influencing treatment dynamics in the psoriasis drugs market?
How are comorbidities affecting demand patterns in the psoriasis drugs market?
Which treatment segment leads the psoriasis drugs market?
Why is topical administration the fastest-growing route in the psoriasis drugs market?
Why does North America lead the psoriasis drugs market?
What is driving growth in Asia Pacific psoriasis drugs market?
Which companies are driving growth in the psoriasis drugs landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization